Published in J Biol Chem on June 21, 2006
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010) 2.33
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov (2012) 1.62
Neonatal Fc receptor and IgG-based therapeutics. MAbs (2011) 1.56
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol (2009) 1.42
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature (2014) 1.35
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J (2012) 1.27
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother (2013) 1.24
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther (2009) 1.17
Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin (2010) 1.15
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
Modern Technologies for Creating Synthetic Antibodies for Clinical application. Acta Naturae (2009) 1.12
Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci (2009) 1.12
Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem (2014) 1.10
The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol (2012) 1.06
Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One (2013) 0.99
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs (2013) 0.98
Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem (2014) 0.98
Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor. Protein Expr Purif (2011) 0.97
Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother (2014) 0.97
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother (2012) 0.95
Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol (2010) 0.94
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A (2015) 0.94
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs (2015) 0.94
Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs (2014) 0.93
IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs (2010) 0.93
pH-selective mutagenesis of protein-protein interfaces: in silico design of therapeutic antibodies with prolonged half-life. Proteins (2013) 0.92
Respiratory syncytial virus market. Nat Rev Drug Discov (2010) 0.90
Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs (2014) 0.90
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem (2012) 0.90
Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol (2014) 0.87
Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs (2012) 0.87
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions. Front Immunol (2015) 0.86
MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother (2015) 0.86
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol (2013) 0.85
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem (2014) 0.85
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev (2015) 0.84
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Mol Cell Proteomics (2014) 0.83
Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. MAbs (2015) 0.83
Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. Br J Pharmacol (2011) 0.83
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs (2014) 0.83
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Deliv Transl Res (2017) 0.82
ADME of biologics-what have we learned from small molecules? AAPS J (2012) 0.82
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. MAbs (2014) 0.82
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. MAbs (2013) 0.82
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs (2016) 0.82
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs (2015) 0.81
Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. MAbs (2016) 0.80
Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs (2015) 0.80
A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry (2015) 0.80
How can we improve antibody-based cancer therapy? MAbs (2010) 0.80
Targeting FcRn for the modulation of antibody dynamics. Mol Immunol (2015) 0.80
Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs (2014) 0.80
Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom (2015) 0.80
Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure. MAbs (2013) 0.80
Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs (2015) 0.79
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs (2015) 0.79
Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity. MAbs (2012) 0.79
Safety, tolerability, and pharmacokinetics of the respiratory syncytial virus-prefusion F-targeting monoclonal antibody with an extended half-life, MEDI8897, in healthy adults. Antimicrob Agents Chemother (2016) 0.79
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration. Proc Natl Acad Sci U S A (2015) 0.79
Chimeric antibodies with extended half-life in ferrets. Influenza Other Respir Viruses (2014) 0.78
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. MAbs (2014) 0.78
Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs (2016) 0.78
Robust expression of the human neonatal Fc receptor in a truncated soluble form and as a full-length membrane-bound protein in fusion with eGFP. PLoS One (2013) 0.78
Stable long-term cultures of self-renewing B cells and their applications. Immunol Rev (2016) 0.78
Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data. MAbs (2016) 0.77
Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations. Mol Biosyst (2013) 0.77
Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs (2015) 0.77
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev (2017) 0.77
Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. MAbs (2016) 0.77
Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice. Immunol Lett (2014) 0.77
Next generation of antibody therapy for cancer. Chin J Cancer (2011) 0.76
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. J Immunol (2015) 0.76
Antibody-based concepts for multipurpose prevention technologies. Antiviral Res (2013) 0.76
Understanding the relationship between biotherapeutic protein stability and solid-liquid interfacial shear in constant region mutants of IgG1 and IgG4. J Pharm Sci (2013) 0.76
Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung. MAbs (2016) 0.76
At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapies. Br J Clin Pharmacol (2014) 0.76
Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs (2016) 0.76
Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn (2015) 0.75
Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques. PLoS One (2016) 0.75
Engineering an Anti-Transferrin Receptor ScFv for pH-Sensitive Binding Leads to Increased Intracellular Accumulation. PLoS One (2015) 0.75
Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics. MAbs (2016) 0.75
Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. MAbs (2017) 0.75
Generation and Characterization of an IgG4 Monomeric Fc Platform. PLoS One (2016) 0.75
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, ExtendedHalf-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother (2016) 0.75
Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life. Front Immunol (2016) 0.75
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. MAbs (2017) 0.75
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med (2010) 2.36
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum (2009) 2.14
Type I interferon: potential therapeutic target for psoriasis? PLoS One (2008) 2.08
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis (2011) 1.91
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol (2010) 1.86
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 1.80
YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol (2008) 1.78
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res (2011) 1.78
Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum (2007) 1.72
Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol (2003) 1.57
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol (2010) 1.41
Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol (2008) 1.34
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother (2005) 1.32
Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol (2006) 1.25
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res (2008) 1.25
Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr (2008) 1.24
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum Genomics Proteomics (2009) 1.22
Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol (2009) 1.19
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res (2007) 1.15
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol (2009) 1.14
Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis (2008) 1.13
Differential EphA2 epitope display on normal versus malignant cells. Cancer Res (2003) 1.12
Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem (2014) 1.10
Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol (2009) 1.09
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther (2010) 1.09
Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol (2006) 1.09
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother (2009) 1.08
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther (2006) 1.08
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs (2015) 1.04
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol (2010) 1.03
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res (2004) 1.00
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol (2011) 0.97
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia (2009) 0.95
Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs (2013) 0.93
The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One (2012) 0.91
Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol Cancer Ther (2013) 0.89
Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respir Res (2010) 0.89
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs (2012) 0.89
Antibody humanization by framework shuffling. Methods (2005) 0.87
Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. J Gen Virol (2008) 0.87
Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-alpha toxin antibody fragment and alpha toxin. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.86
CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol (2014) 0.85
Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. J Mol Biol (2011) 0.84
Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs (2015) 0.84
Tailor-made antibody therapeutics. Methods (2005) 0.84
Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg Med Chem Lett (2004) 0.83
Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing. Virus Genes (2010) 0.83
Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon alpha-2A. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.82
Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol (2007) 0.81
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. MAbs (2015) 0.81
Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem (2003) 0.81
Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. Leuk Lymphoma (2004) 0.80
In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-kappaB activation. Int Immunopharmacol (2002) 0.80
Humanized antibodies and their applications. Methods (2005) 0.78
Targeting the junction of CɛmX and ɛ-migis for the specific depletion of mIgE-expressing B cells. Mol Immunol (2012) 0.77
C-3 Amido-indole cannabinoid receptor modulators. Bioorg Med Chem Lett (2002) 0.77
Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha. Mol Med (2008) 0.77
Alterations in Fas (CD 95/Apo-1) and Fas ligand (CD178) expression in acute promyelocytic leukemia during treatment with ATRA. Leuk Lymphoma (2004) 0.77
A mammalian expression system for high throughput antibody screening. J Immunol Methods (2013) 0.77
Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies. Mol Immunol (2004) 0.76
Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.76
A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody Fragments. Biomacromolecules (2016) 0.75
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression. Br J Haematol (2002) 0.75
Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody. Microbiol Spectr (2014) 0.75